Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Plimoth Trust Co. LLC

Plimoth Trust Co. LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 53.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,132 shares of the biopharmaceutical company's stock after selling 1,324 shares during the period. Plimoth Trust Co. LLC's holdings in Regeneron Pharmaceuticals were worth $994,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Meyer Handelman Co. lifted its position in shares of Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company's stock worth $3,485,000 after purchasing an additional 435 shares in the last quarter. Stifel Financial Corp boosted its stake in Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company's stock valued at $25,537,000 after acquiring an additional 3,385 shares during the last quarter. LPL Financial LLC boosted its stake in Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company's stock valued at $33,522,000 after acquiring an additional 3,479 shares during the last quarter. Cavalier Investments LLC boosted its stake in Regeneron Pharmaceuticals by 88.6% during the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company's stock valued at $3,651,000 after acquiring an additional 2,084 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company's stock valued at $4,351,000 after acquiring an additional 1,221 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on REGN. Barclays increased their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a research note on Tuesday, January 23rd. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a "neutral" rating in a report on Tuesday, February 6th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Friday, January 5th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an "outperform" rating in a report on Monday, February 5th. Finally, Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a report on Wednesday, March 13th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $968.67.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company's stock, valued at $1,325,338. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company's stock, valued at $1,325,338. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company's stock, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $5.41 during midday trading on Tuesday, hitting $943.89. The company had a trading volume of 305,891 shares, compared to its average volume of 489,088. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The business's 50 day simple moving average is $959.57 and its two-hundred day simple moving average is $886.82. The stock has a market cap of $103.60 billion, a PE ratio of 27.14, a P/E/G ratio of 2.75 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the previous year, the company earned $10.96 earnings per share. The business's revenue was up .6% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.